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Amphetamine (2.0 mg/kg) produce hypo-activity around hour 20 post-
administration in rat (White, Feldon & White, 2004). The hypo-activity may be an 
a pect of acute withdrawal, because other indications of withdrawal a.re present at the 
same time, including REM sleep rebound, unwill ingne to work for reward, and a 
Haloperidol cue state (Barr & Phillips, 1999; Barrett, White & Caul, 1992; Edgar & 
Seidel, 1997). The purpo e of the e studies was to investigate the dopaminergic 
mechanisms involved in producing amphetamine-induced hypo-activity. More 
specifical ly, the goal was to study the contribution of different dopamine receptor 
subtypes to the phenomenon. 
In order to pursue this objective two experiment were conducted. In both 
experiments, male Wistar rats were individually housed in plastic cubicles, where 
they were on a 12-12 hr light-dark cycle and had free acces to food and water. A 
camera mounted above each cubicle was connected to a computer by a multiplexer. 
Tracking software used camera images to quantify activity in terms of total distance 
moved per hour. Different group of rat were given subcutaneous administration of 
different doses of SKF 81297 (SKF), a dopanu ne 01 receptor agonist, or of 
Quinpirole, a dopamine D2 receptor agonist. In Experiment 1 different groups of rats 
were given administrations of saline, 2.0 mg/kg amphetamine, 0.2 mg/kg SKF, 0.4 
mg/kg SKF, 0.2 mg/kg Quinpirole, or 0.4 mg/kg Quinpirole. In Experiment 2 
different groups of rats were given combined administrations of 0.0 SKF/ 0.4 
Quinpirole, 0.2 SKF/ 0.4 Quinpirole, 0.4 SKF/ 0.4 Quinpirole or 0.8 SKF/ 0.4 
Quinpirole. All treatments occurred at the start of the light period and were separated 
by at least a 48-hr interval. Activity was monitored for 33 hr after each treatment. 
In Experiment 1 only amphetamine produced hypo-activity 20 hr post-
administration. Selective stimulation of D 1 or D2 receptors was not sufficient to 
produce such hypo-activity. In Experiment 2 the two higher dose combinations (0.4 
SKF/ 0.4 Quinpirole and 0.8 SKF/ 0.4 Quinpirole) produced hypo-activity 20 hr post-
administration. The lower dose combinations did not. 
Combined stimulation of D l and D2 receptors above a threshold level by 
amphetamine may be sufficient to initiate amphetamine-induced hypo-activity. This 
raises the possibility that the cascade of events by which amphetamine produces other 
indications of acute withdrawal is also initiated by the short term activation of D l and 
D2 receptors. The methods used here may provide a convenient animal model with 
which to further study the determinants of amphetamine-induced hypo-activity and 
acute withdrawal. 
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Dopamine Dl and D2 Receptor Interaction 
May Initiate Amphetamine-Induced Hypo-Activity in Rats 
Research has shown that certain doses of amphetamine can cause hypo-
activity 20 hr post-treatment in rats (White, Feldon & White, 2004). The objective of 
the current research was to evaluate whether certain dopaminergic mechanisms might 
have contributed to this amphetamine-induced hypo-activity. 
In order to pursue this objective, different groups of rats were given different 
doses of SKF 81297, a DI-like receptor agonist, or of Quinpirole, a D2-like receptor 
agonist; or they received doses of the agonists combined. Effects on activity were 
evaluated by housing rats in individual stations where activity was continuously 
monitored. If a particular treatment had the ability to produce hypo-activity, then the 
specific mechanism affected might also be involved in amphetamine's ability to 
induce hypo-activity. 
In the remainder of this introduction I will do the following. I. will describe 
some of amphetamine's immediate effects in humans. Because I am focusing on 
activity, I will then describe amphetamine's immediate and longer-term effects on 
activity and on other measures in rats. Amphetamine has several time-dependent 
effects, so I will introduce a terminological distinction that clarifies what I am trying 
to account for. Amphetamine affects multiple neurotransmitters, so I will describe 
evidence that justifies the focus on dopamine (DA). I will then review dopaminergic 
mechanisms, with a focus on dopamine pathways and the structure and function of 
the dopamine receptor subtypes. Then, I will explain why activity is a good 
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behavioral measure. Finally, I will talk about specific goals and hypotheses and 
conclude with the significance of this research. 
Immediate effects in humans. The immediate effects of amphetamine in 
humans are well known (reviewed in Julien, 2004; Segal & Kuczenski, 1994). During 
the first several hours post-administration, amphetamine produces signs of autonomic 
arousal including an increase in blood pressure, heart rate, respiration, metabolism, 
and body temperature, as well as dilatation of the pupils. Amphetamine also produces 
signs of cognitive, motivational, and emotional arousal including an increase in 
alertness, increased energy, and a feeling of well-being and euphoria (Julien, 2004). 
Immediate and longer-tenn effects in rats. The immediate effects of 
amphetamine on the activity of rats are dose-dependent. A moderate dose of 1.0 
mg/kg produces an increase in locomotor activity and rearing, as well as mild sniffing 
and head bobbing. A moderately high dose of 2.0 mg/kg produces an increase in 
locomotor activity intermixed with low gauge stereotypy. A high dose of 4.0 mg/kg 
produces a multi-phasic pattern: An initial increase in locomotion is replaced by 
intense stereotypy which is then followed by another increase in locomotion 
(reviewed in Feldman, Meyer & Quenzer, 1997). 
Additional immediate effects of amphetamine in rats include autonomic 
changes. Drug discrimination, conditioned place preference, and drug self-
administration studies indicate that amphetamine produces discriminable internal 
cues, some of which are rewarding (reviewed in Hoffman, 1989). 
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Amphetamine also has some longer term effects on activity. White et al. 
(2004) found that male Sprague-Dawley rats, when given 1.0 mg/kg amphetamine, 
were hypo-active around hours 19-21 post-treatment. White and White (in press) gave 
male Wistar rats a range of amphetamine doses (1.0 mg/kg, 2.0 mg/kg and 4.0 
mg/kg). They found that the 1.0 mg/kg dose did not produce hypo-activity around 
hour 20 post-treatment but that the 2.0 and 4.0 mg/kg doses did. 
In addition to immediate effects and effects 20 hr after adntinistration, 
amphetantine and other psychomotor stimulants enhance activity and autonontic 
function for several hours beginning approximately 24 hr after adntinistration 
(Tomatzky & Miczek, 1999; White et al., 2004; White & White, in press). The 
changes may indicate a recovery state. 
Induction and expression. Amphetamine is followed by different effects at 
different times. Therefore, it is useful to introduce new terntinology in order to clarify 
my interest. 'Induction' will be used to refer to the events that must occur in the short 
term to produce the hypo-activity near hour 20. 'Expression' will be used to refer to 
the events involved in the manifestation of the hypo-activity. I am interested in 
investigating what form of short-term dopantinergic stimulation is sufficient to 
produce hypo-activity 20 hr later, therefore, I am interested in the process of 
induction. 
The purpose of this research was not to investigate how induction and 
expression ntight be linked. However, the opponent process theory (Solomon & 
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Corbit, 1974) and the distinction between within and between system adaptations 
(Koob & Bloom, 1988) explain how induction and expression could be linked. 
According to opponent process theory, intense states are followed later by a 
rebound in the opposite direction (Solomon & Corbit, 1974). The opponent process 
theory of drug addiction describes how the withdrawal from a drug can promote drug 
dependence and addiction through negative reinforcement (Barr, Markou & Phillips, 
2002). Thus, an individual will try to restore hedonic equilibrium by self medication 
through drug intake. 
A within-system adaptation produces a rebound when "the primary cellular 
response responsible for the acute hedonic effects of the drug would itself adapt to 
oppose and neutralize the drug's effects; persistence of the opposing effects after the 
drug disappears would produce the motivational withdrawal response." A between-
systems adaptation produces a rebound when "cellular and molecular systems 
different from those responsible for the acute hedonic effects of the drug, triggered by 
the changes in the primary drug response neurons, would contribute to or produce the 
motivational effects of withdrawal after drug removal (Koob & Bloom, 1988)." In 
other words, in a within-system adaptation, the same mechanisms that are involved in 
induction are also involved in expression. Alternatively, in a between-systems 
adaptation, different mechanisms are involved in induction and expression. How 
these processes might be applicable to this research will be discussed in more detail 
later. 
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Justification for dopamine involvement. Amphetamine is an indirect agonist of 
catecholamines, including dopamine, norepinephrine and serotonin. For example, 
amphetamine promotes the release of dopamine from the presynapse, and it blocks 
reuptake of dopamine and norepinephrine and serotonin. Amphetamine can also 
inhibit the storage of dopamine in vesicles and inhibit the destruction of dopamine by 
enzymes (Julien, 2004). The stimulation of one or more catecholaminergic receptors 
in the short-term by amphetamine would appear to be involved in induction. 
I focused on dopamine because non-selective stimulation of dopaminergic 
receptors in the short-term appears to produce hypo-activity near hour 20. 
Apomorphine is a non-selective direct agonist of dopamine. White, Mattingly, Duke, 
Liu, Dunkman, Charles, and White (2002) gave male Wistar rats 1.0 mg/kg or 2.0 
mg/kg apomorphine and found that the rats were hypo-active 19-21 hr post-treatment. 
This time course parallels the time course seen with amphetamine. The study suggests 
that amphetamine's ability to produce hypo-activity might be mediated via dopamine 
receptors. 
Other research has suggested that dopamine might be involved in the 
expression of hypo-activity. Barrett, White, and Caul (1992), Persico, Schindler, 
Zaczek, Brannock, and Uhl (1995), and Tonge (1974) have all found molecular and 
neurochemical changes in dopamine 20 hr after amphetamine treatment that might be 
related. 
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Because research has established that dopamine is involved in amphetamine-
induced hypo-activity, it becomes reasonable to investigate the specific dopaminergic 
mechanism/s that might underlie the phenomenon. 
Review of dopaminergic mechanisms. Dopamine is a main neurotransmitter 
that has an important role in the control of motor activity, reward-related 
mechanisms, and emotional and cognitive processes. The dopaminergic system 
includes several pathways. The main dopaminergic pathways in the brain are the 
nigrostriatal, mesolimbic, and mesocortical. The nigrostriatal pathway projects from 
the substantia nigra to the striatum. The mesolimbic pathway projects from the vental 
tegmental area (VTA) to the nucleus accumbens, olfactory tubercle, septum, and 
amygdala. Finally, the mesocortical pathway projects from the VTA to the prefrontal 
cortex (Julien, 2004; Wishaw, Kolb & Wishaw, 2003). 
Five dopamine receptor sub-types have been identified on the basis of 
structural, pharmacological, and functional characteristics. The DI and D5 subtypes 
are categorized under the DI-like family and the D2, D3 and D4 subtypes are 
categorized under the D2-like family. In these studies I will use pharmacological 
agents to selectively stimulate the two main dopamine receptors, the DI and D2 
receptors. After I review the molecular structure, the localization and the functions of 
the DI receptor, I will do the same for the D2 receptor. 
The DI-like receptors are seven transmembrane domain metabotrophic 
receptors. Structurally the DI-like receptor has the N-terminus localized on the 
extracellular surface, a long C-terminus which projects into the cytosol, and a small 
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third cytoplasmic loop. DI-like receptors are found in the hypothalamus, thalamus, 
ofactory tubercle, substantia nigra pars reticulata, striatum and nucleus accumbens. 
DI-like receptors are found primarily at the post-synapse (Sibley, Monsuma & Shen, 
1993). 
DI-like receptor activation has been found to increase motor activity. Dl 
receptor stimulation with agonists elicits locomotion, grooming and rearing in rats 
(Molloy & Wadington, 1984 ). Direct infusion of D 1 agonist into the dorsal striatum 
or nucleus accumbens elicits hyperactivity and the development of behavioral 
sensitization to the locomotor-activating effects of amphetamine. Furthermore, Dl 
agonist infusion into the nucleus accumbens produces a conditioned place preference 
and supports drug discrimination, whereas Dl anatagonists attenuate these effects 
(Waddington, 1986). 
The D2-like receptor is also a seven transmembrane domain metabotrophic 
receptor. However, structurally the D2-like receptor differs from the DI-like receptor 
because its C-terminus is small and its third cytoplasmic loop is large. D2-like 
receptors are found in the ventral tegmental area, granule area of the hippocampal 
formation, substantia nigra pars compata, septal region, cingulate, nucleus 
accumbens, amygdala and prefrontal region. D2-like receptors are found at both the 
pre- and post-synapse (Sibley et al., 1993). 
D2-like receptor stimulation has been found to increase locomotion, sniffing 
and snout contact (Eilam, Golani & Szechtman, 1989; Molloy & Waddington, 1985; 
Walters, Bergstrom, Carlson, Chase & Braun, 1987). D2 agonists do not produce a 
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conditioned place preference but do produce a discriminative stimulus effect (Nielsen 
& Scheel-Krueger, 1986). D2 receptor stimulation has been found to produce 
behavioral effects similar to those of non-selective dopamine agonists. 
Activity as the dependent variable. The main dependent variable m this 
research was an activity measure. An activity measure has several advantages. First, 
the rat circadian activity pattern is well understood: Activity occurs in bouts that are 
separated by one to several hours, and most activity occurs during the dark period. 
Second, the effects of drugs on activity can be easily identified against this well 
known background. Finally, changes in activity can be used to make inferences about 
the drug-induced state that an animal is in. 
Goals and hypothesis. The purpose of this research was to investigate which 
dopaminergic receptors produce amphetamine-induced hypo-activity. Specifically: 
• In Experiment 1, activity was measured following one of several 
treatments. Treatments included administration of amphetamine, 
saline, and different doses of either dopamine DI receptor agonist 
(SKF 81297) or dopamine D2 receptor agonist (Quinpirole). 
• In Experiment 2, activity was measured following one of several 
treatments. Treatments included administration of different doses of 
D1 receptor agonist (SKF 81297) combined with D2 receptor agonist 
(Quinpirole). 
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The ability either of a selective agonist or of the agonists in combination to 
produce hypo-activity would indicate. which specific dopaminergic receptors are 
involved in amphetamine-induced hypo-activity. 
Significance and implications. The longer-term effects of amphetamine need 
to be studied for various reasons. Acute administration of psychostimulants is not 
thought to produce symptoms of hangover. However, the presence of hypo-activity 
20 hr post-amphetamine administration suggests that there may be costs to even acute 
amphetamine use. Longer term motivational processes might be affected by 
amphetamine. In particular, amphetamine-induced hypo-activity may compete with 
psychological processes necessary for effective task performance. Amphetamine-
induced hypo-activity may even be an indicator of an acute withdrawal syndrome. 
This research may help us identify novel side effects produced by amphetamine 
administration. 
Additionally, this research may promote the development of an animal model 
of amphetamine-induced acute withdrawal. We eventually want to use such a model 
to understand the mechanisms underlying different symptoms of acute withdrawal. 
Information regarding the symptoms present during amphetamine-induced acute 
withdrawal in humans has not been obtained, primarily because human drug use 
occurs under very complex circumstances. Inducing these symptoms in humans under 
controlled circumstances would not be ethical. Hence, it is necessary to use an animal 
model approach. Understanding the psychological processes and identifying the 
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mechanisms that contribute to amphetamine-induced hypo-activity and acute 
withdrawal may help us identify potential treatments for amphetamine abuse. 
Experiment 1: Selective Dopamine Receptor Activation 
Treatment with either amphetamine or apomorphine produces hypo-activity 
20 hr later, suggesting that the hypo-activity may be dependent on short term 
stimulation of dopaminergic receptors. Apomorphine is a nonselective dopamine 
agonist: It activates both DI and D2 receptors. Consequently, whether apomorphine 
(and by inference, amphetamine) produces hypo-activity by activating the DI 
receptor subtype, the D2 receptor subtype, or both is uncertain. Experiment I 
investigated whether hypo-activity 20 hr after treatment could be elicited by 
stimulating either DI or D2 receptor subtypes alone. 
To justify my methods, I will briefly review the dopamine agonists that I used. 
First, I will review SKF 81297, a selective direct DI-like agonist. Then I will review 
Quinpirole, a selective direct D2-like agonist. Because I am measuring activity, I will 
describe how the drugs affect immediate activity and why they might result in hypo-
activity in the longer-term. Finally, I will identify neural structures that may be 
involved in the agonist-induced behaviors. 
Hypotheses. 
• Selective dopamine DI receptor activation with the agonist SKF 
81297 would produce hypo-activity 20 hr post-treatment. 
• Selective dopamine D2 receptor activation with the agonist Quinpirole 
would produce hypo-activity 20 hr post-treatment. 
If either selective agonist (SKF 81297 or Quinpirole) produced hypo-activity 
20 hr later, then amphetamine might do the same via a similar mechanism. 
DJ-like agonist: SKF 81297. SKF 81297 (SKF) is a full dopamine DI-like 
receptor agonist. The agonist is a benzazepine derivative. Andersen and Jansen 
( 1990) showed, with a measure of adenylate cyclase stimulation, that SKF has a very 
high affinity for DI receptors. 
A number of studies have shown the immediate effects of SKF 81297 on 
activity in rats (Alleweireldt, Weber, Kirschner, Bullock & Neisewander, 2002; Arnt, 
Hyttel & Sanchez, 1992; Chausmer & Katz, 2002; Gendreau, Gariepy, Petitto & 
Lewis, 1997; Heijtz, Beraki, Scott, Aperia & Forssberg, 2002; Reavill, Bond, 
Overend & Hunter, 1993). Heijtz et al. (2002), utilizing a range of doses (0.3, 3.0 and 
IO mg/kg), showed the biphasic effect SKF has on motor activity in the rat. SKF 
appeared to have an initial short inhibition on activity that was then followed by a 
longer-lasting increase in activity. The inhibitory period did not appear to involve an 
increase in stereotypy. SKF has also been found to increase grooming behavior in the 
rodent. In addition to the immediate motor effects of SKF, the DI agonist also 
produces immediate autonomic and physiological arousal effects similar to those of 
cocaine and amphetamine (Chausmer & Katz, 2002). For example, Reavill et al. 
(1993) found that SKF could replace cocaine and amphetamine in drug 
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discriminiation studies. Rosenzweig-Lipson and Bergman (1993) found that SKF 
acted as a partial substitute for cocaine in rats. 
DI receptors are primarily localized post-synaptically, especially in the 
striatum, nucleus accumbens, olfactory tubercle and the cerebral cortex (Sibley et al., 
1993). Additionally, these areas have been found to be stimulated with SKF 
administration (Reavill et al., 1993; Rosenzweig-Lipson et al., 1993). Heijtz et al. 
(2002) suggested that the stimulatory effects of SKF are mediated via the striatum, 
whereas the inhibitory effects are mediated via the medial prefrontal cortex. 
SKF administration could produce longer term activity patterns similar to 
those seen following amphetamine administration. The areas in which DI receptors 
are located and that SKF stimulates are involved in the mediation of motor activity. 
Consistent with a within system adaptation, the same DI receptors stimulated by 
amphetamine in the short term could be involved in the longer term expression of 
hypo-activity. 
administration. 
Therefore, SKF could produce hypo-activity 20 hr after 
D2-like agonist: Quinpirole. Quinpirole is a dopamine D2-like receptor 
agonist. Andersen and Jansen (1990) showed that Quinpirole has a high affinity for 
both D2 and D3 receptors, with a greater affinity for D3 receptors. However, 
Quinpirole is regularly used as a D2-Iike receptor agonist. 
A number of studies have shown the immediate effects of Quinpirole on 
activity in rats (Eilam, Golani & Szechtman, 1989; Eilam & Szechtman, 1989; Van 
Hartesveldt, 1997). Eilam and Szechtman (1989) showed the biphasic locomotor 
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effects of Quinpirole by administering a range of doses to rats. The researchers found 
that moderate to high doses (0.5 - 8 mg/kg) produced an initial inhibition of activity 
followed by stimulation of activity that lasted for about 2 hr. Others such as Van 
Hartesveldt (1997) showed that Quinpirole was similar in locomotor-activating effect 
to apomorphine, a non-selective dopamine agonist. The study found that lower 
subcutaneous doses (0.0, 0.02 or 0.2 mg/kg) could also elicit a biphasic activity 
profile. However, Quinpirole administration did not produce stereotypy. 
Quinpirole appears to produce activity via the striatum and the nucleus 
accumbens. Van Hartesveldt, Cottrell, Potter, and Meyer (1992) found that 
Quinpirole injected into the striatum but not into the nucleus accumbens produced the 
same locomotor effects as a systemic administration. Others such as Mogenson and 
Wu (1991) found that injection of Quinpirole into the nucleus accumbens reduced 
amphetamine-elicited locomotion. Mogenson and Wu (1991) and Furmidge, Tong, 
Petry, and Clark (1991) suggested that the initial inhibitory effects of Quinpirole may 
be mediated by DA receptors in the nucleus accumbens, whereas the secondary 
stimulatory effects may be due to the striatum. These areas are well known to be 
involved in locomotion. 
Quinpirole administration could produce longer-term activity patterns similar 
to those seen following amphetamine administration. D2 receptor stimulation 
produces many of the same behavioral effects as non-selective dopamine agonists, 
though not as robustly. Consistent with a within system adaptation, the same D2 
receptors stimulated by amphetamine in the short term could be involved in the 
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longer term expression of hypo-activity. Therefore, Quinpirole could produce hypo-
activity 20 hr after administration. 
Method 
Subjects 
The subjects were 64 male rats of the Wistar strain, purchased from Harlan 
(Indianapolis, IN). Prior to the start of the study all rats were housed in pairs in the 
departmental colony in a temperature of 20°C - 22°C and on a 12-hr light/ 12-hr dark 
cycle. Rats had free access to food (5001 Rodent Diet, Lab Diet) and water, and 
weighed between 300 and 400 g at the start of the experiment. Animals were treated 
in accordance with ethical guidelines established by the National Institutes of Mental 
Health and approved by Morehead State University IACUC. 
Apparatus 
Sixteen stations were used (see Figure 1). The 16 stations were located in two 
well-isolated rooms (each approximately 1.8 m X 2.1 m X 2.6 m high). Within each 
room there were eight sound attenuating, wooden compartments (58 cm X 42 cm X 
71 cm high, with a shelf 58 cm from the bottom). The interior of each compartment 
was white and each compartment had a fan (Sunon, sfl 1580A) mounted in the upper 
portion of one side wall for ventilation and to mask out sound. A light fixture (Lampi-
Pico accent light, 4-W) was mounted in the middle of the back wall. The lights were 
used to produce the same 12-hr light/ 12-hr dark cycle in all stations. 
In each compartment was a plastic cubicle (40 cm X 20 cm). The floor of the 
cubicle was a black metal pan, which contained a thin layer of micro-waved topsoil to 
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Figure 1. Picture of 16 stations used to house and record activity of rats. Plus symbols 
indicate software tracking the activity of rats. 
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provide absorbency and minimize reflections. The right wall had two· vertical 
masonite panels, one of which held a drinking tube (8 cm from the front of the 
cubicle and 6 cm from the floor) attached to a 250 ml bottle of water. The other panel 
contained an opening (15 cm from the front and 6 cm from the floor) to a feeding bin, 
which held 200 g of powdered meal (Lab Diet, Rodent Diet 5001). In the ceiling of 
the compartment, and centered 50 cm above the floor of each cubicle, was a 
monochrome infrared camera (Super Circuits #DC 12-500R). The lens of the camera 
was surrounded with IR-emitting diodes to monitor locomotor activity in the dark. A 
paper disk encircled the lens so that direct light could not shine on the floor below. 
The cameras were connected by cables to a monochrome multiplexer (Robot-
Duplex Digital Video Multiplexer, DMV16Q), which combined images from the 
cameras in each of the 16 stations into one image for recording and quantification. 
The multiplexer was connected to a video recorder (JVC, SR-VlOU), a monitor (14" 
Trinitron high resolution video monitor, ECM-1402H), and a computer. The 
computer (Dell, M782p) contained a piccolo frame grabber. An EthoVision Pro 3.0 
Video Tracking, Motion Analysis and Behavior Recognition System collected and 
analyzed the data. Each animal was tracked within an area corresponding to the 
dimensions of the floor. The system was programmed to take two samples per 
second. The gray scaling method was used in object detection. Control equipment 
was located in an adjacent room. 
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Drugs 
SKF 81297 (0.4 mg/ml and 0.2 mg/ml) (Sigma) was mixed in distilled water. 
Quinpirole (0.4 mg/ml and 0.2 mg/ml) (Sigma) was mixed in saline. Amphetamine 
(2.0 mg/ml) (Sigma) was mixed in saline. All drugs were injected subcutaneously in 
the back of the neck in a volume of 1.0 ml/kg. Saline was the control treatment. 
Procedure 
The experiment included 6 treatment groups: saline (N= 10), amphetamine 
(N=l2), 0.2 Quinpirole (N=l2), 0.4 Quinpirole (N=l2), 0.2 SKF (N=8), and 0.4 SKF 
(N=8). The first 4 groups were run in one series of studies, and the last 2 groups were 
run in a separate series. Throughout each study rats were continuously housed in one 
of the stations in a 12-hr light/ 12-hr dark cycle and allowed free access to food and 
water. 
Figure 2 displays a schematic diagram of the basic procedure. Up to 2 
habituation ("Hab") cycles were run. No treatments were given during habituation 
cycles. Rats then received a series of control treatments followed by a series of drug 
treatments. All treatments occurred at the start of the light cycle. During the first 
control treatment, each rat was removed in turn from its station, weighed and 
vigorously rubbed on the back of the neck. During subsequent control treatments 
("Saline"), animals also received a subcutaneous injection of saline (0.5 ml) into the 
nape of the neck. Control treatments were separated by 48 hr. Control treatments 
were given until patterns of activity across groups were similar for 2 consecutive 
control-treatment cycles. While a rat was being treated, its apparatus was maintained. 
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by light and dark boxes. Each row is a day. 
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Maintenance of the apparatus consisted of wiping down the pan, adding new top soil, 
and replenishing food and water. Treatment and maintenance took approximately 2 
min per station. 
Following control treatment cycles, 2 drug treatments cycles were run 
("Drug"). Drug treatment cycles were similar to control treatment cycles except that 
different groups of rats received different drug treatments. Drug treatments included 
saline, 2.0 mg/kg amphetamine, 0.2 mg/kg Quinpirole, 0.4 mg/kg Quinpirole, 0.2 
mg/kg SKF 81297, or 0.4 mg/kg SKF 81297. All drugs were injected subcutaneously 
into the back of the neck in a volume of 1.0 ml/kg. At least 72 hr elapsed between 
drug treatments to allow drug to be cleared from the body. Throughout the study, 
monitoring began at the same time in all stations -- at lights on and shortly before 
treatments began. Activity of animals was monitored continuously for 33 hr. 
Additional station and animal maintenance occurred between treatment cycles, when 
animals were not being monitored. 
Data Analysis 
Tracking software was used to quantify total distance moved for each rat into 
10-min bins. Though monitoring began at lights on, for each rat activity was 
quantified beginning with the 10-min bin following treatment. Data were then 
combined into 33 1-hr bins for each rat. All hourly activity totals were expressed as a 
percentage of each rat's mean control value. To obtain this mean for each rat, hours 
2-25 were averaged across the last 2 control cycles. Hourly percent control values 
were averaged for each rat across these 2 control cycles and across the 2 drug 
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treatment cycles. Activity was also averaged into 3-hr bins for each rat. Activity was 
then averaged across subjects in a treatment group. 
Changes in immediate activity (hours 1-6 post-treatment) and longer-term 
activity (hours 7-33 post-treatment averaged into 3-hr bins) were analyzed with an 
analysis of variance (ANOV A). One-way between and within ANOV As were 
performed on significant main effects. All significant results were followed-up with 
Fisher's PLSD post hoc analysis or paired t-tests. 
Results 
Immediate results. Figure 3 shows mean activity (as a percentage of control) 
for the first 6 hr post-treatment for all 6 groups during the control cycles. Activity 
appeared to be elevated for the first hour after treatment and then to decline to normal 
levels for hours 2-6 post-treatment. A six ( drug treatment groups) by six (post-
treatment hours) mixed two-way analysis of variance (ANOVA) was conducted. No 
significant effect of group or significant group by hour interaction was obtained, F(5, 
56) = 0.717, p > .05 and F(25, 280) = 0.80, p > .05. A significant effect of hour was 
obtained, F(5, 280) = 116.206, p < .0001. Fisher's PLSD post hoc analysis indicated 
that overall activity was significantly higher during the first hour post-treatment than 
during all other hours (p < .0001). No other differences were found. 
Figure 4 shows mean activity (as a percentage of control) for the first 6 hr 
post-treatment for all 6 groups during the treatment cycles. The amphetamine group 
appeared to be elevated in activity through hour 5. All other treatment groups showed 
a decline to normal activity levels after the first or second hour. Again, a six (drug 
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Figure 3. Mean activity during hr 1-6 post-administration for saline, amphetamine, 
0.2 mg SKF, 0.4 mg SKF, 0.2 mg Quinpirole, and 0.4 mg Quinpirole groups during 
control cycles.± SEMbars are shown. 
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Figure 4. Mean activity for hr 1-6 post-administration for saline, amphetamine, 0.2 
mg SKF, 0.4 mg SKF, 0.2 mg Quinpirole and 0.4 mg Quinpirole groups during drug 
cycles. ± SEM bars are shown. 
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treatment groups) by six (post-treatment hours) mixed two-way ANOVA was 
conducted. Significant effects of group and hour were obtained, as well as a 
significant interaction, F(5, 56) = 98.373, p < .0001, F(5, 280) = 114.310, p < .0001 
and F(25, 280) = 16.525, p < .0001. Additional analyses were conducted to compare 
the activity of groups at each hour and the activity within each group across hours. 
First, one-way ANOV As were conducted between groups at each hour and 
additional Fisher's post hoc analyses were conducted to examine significant effects. 
Groups differed during the first hour post treatment, F(5, 56) = 38.698, p < .0001. 
The amphetamine group was greater in activity than all other groups, ps < .0001, and 
both the low and the high dose SKF groups were greater in activity than the 
Quinpirole and saline groups, ps < .0005. Groups also differed in the second hour 
post-treatment F(5, 56) = 77.181, p < .0001. The amphetamine group was again 
greater in activity than all other groups, ps < .0001. The high dose Quinpirole group 
(0.4 mg/kg) was significantly greater in activity than the low dose Quinpirole group, 
the SKF groups and the saline group, ps < .05. Groups also differed during hours 3 
and 4, F(5, 56) = 45.696 and 7.845, ps = < .0001. During these hours the activity of 
only the amphetamine group was elevated, ps < .0001. By hour 6 post-treatment there 
were no group differences in activity, ps > .05. 
Second, separate one-way within group ANOV As were conducted for each 
treatment group. All groups showed a significant decrease in activity across hours, 
F(5, 45) = 18.628, F(5, 55) = 28.125, F(5, 35) = 111.652, F(5, 35) = 547.702, F(5, 
55) = 20.521 and F(5, 55) = 60.419, allps < .0001, for saline, amphetamine, 0.2 SKF, 
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0.4 SKF, 0.2 Quinpirole and 0.4 Quinpirole groups, respectively. For the 
amphetamine group, activity declined from hours 1 to 3, 3 to 4 and 4 to 5, ps < .0001. 
For the 0.2 SKF group, activity declined from hours 1 to 2, p < .0001. For the 0.4 
SKF group, activity declined from hours 1 to 2 and 2 to 3, ps < .0001. For the 
Quinpirole groups, activity declined from hours 1 to 2 and 2 to 3, ps < .005 and 
.0001. Finally, for the saline group, activity declined from hours 1 to 2, p < .0001. 
Figure 5 shows activity (as centimeters moved) in 10-min bins for the first 3 
hr post-treatment. The figure shows activity for the 0.2 mg/kg and 0.4 mg/kg SKF, 
0.2 mg/kg and 0.4 mg/kg Quinpirole and saline groups. The function for the 0.4 
Quinpirole group was biphasic, whereas the functions for the other groups were 
monotonically decreasing. 
Longer-term effects. Figure 6 shows mean activity (as a percentage of control) 
averaged across 3-hr bins for hours 7-33 post-treatment for all 6 groups during the 
control cycles. Activity appeared to be lower during the light-period bins than during 
the dark-period bins and appeared to be particularly elevated during the last dark-
period bin. A six (drug treatment groups) by nine (post-treatment hour bins) mixed 
two-way ANOV A was conducted. No significant effect of group or significant group 
by hour interaction was obtained, F(5, 56) = 0.725, p > .05 and F(40, 448) = 1.367, p 
> .05. A significant effect of hour was obtained, F(8, 448) = 400.552, p < .0001. 
Fisher's PLSD post hoc analysis indicated that overall activity was significantly 
higher during hours 22-24 than at other times and was significantly higher during the 
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• 
dark-period bins (13-15, 16-18, 19-21 and 22-24 hr bins) compared to the light-period 
bins, ps < .0001. 
Figure 7 shows mean activity (as a percentage of control) averaged across 3-hr 
bins for all 6 groups during the treatment cycles. Again, activity appeared to be lower 
during the light-period bins than during the dark-period bins and appeared to be 
elevated during the last dark-period bin. However particular groups appeared to differ 
during the dark period. Specifically, the activity of the amphetamine group appeared 
to decline from the 13-15 hr bin to the 19-21 hr bin. This apparent decline in activity 
was not seen in the other groups. Another six (drug treatment groups) by nine (post-
treatment hour bins) mixed two-way ANOV A was conducted. No significant effect of 
group was obtained, F(5, 56) = 2.230, p > .05. A significant effect of hour and a 
significant group by hour interaction were obtained, F(8, 448) = 313.917, p < .0001 
and F(40, 448) = 1.518, p < .05. 
One-way ANOV As were conducted between groups at each of the 3-hr dark-
period bins, and additional Fisher's post hoc analyses were conducted to examine 
significant effects. Group differences were obtained for the 13-15 hr bin, F(5, 6) = 
3.233, p < .05. The amphetamine and two Quinpirole groups displayed less activity 
than the saline group, ps < .05. Groups did not differ in activity during the 16-18 hr 
bin, F(5, 56) = 2.231, p > .05. However, differences in activity were obtained 
between groups during the critical 19-21 hr bin, F(5, 56) = 3.392, p < .01. The 
activity of the amphetamine group was found to be significantly less compared to 
saline, 0.2 SKF, 0.2 Quinpirole and 0.4 Quinpirole groups during the 19-21 hr bin, ps 
26 
< .05, and trends were obtained for the 0.4 SKF group, p = 0.06. No other differences 
between groups were obtained. By the 22-24 hr bin, no differences between groups 
were obtained, F(5, 56) = 1.179,p > .05. 
Additional, separate one-way within group ANOV As were conducted for each 
treatment group across time. Significant differences were obtained for all groups 
across time, F(8, 72) = 35.836, p < .0001, F(8, 88) = 66.06, p < .0001, F(8, 56) = 
57.443, p < .0001, F(8, 56) = 43.177, p < .0001, F(8, 88) = 89.887, p < .0001 and 
F(8,88) = 57.519, p < .0001, for saline, amphetamine, 0.2 SKF, 0.4 SKF, 0.2 
Quinpirole and 0.4 Quinpirole groups, respectively. For the amphetamine group, 
activity declined from the 13-15 hr bin to the 19-21 hr bin. The SKF, Quinpirole and 
saline groups did not display significant differences in levels of activity across the 13-
15, 16-18 and 19-21 hr bins, ps > .05. Activity for all groups was less during the 13-
15, 16-18 and 19-21 hr bins than during the 22-24 hr bin, ps < .0001. To summarize, 
the main difference compared to the control condition was that the amphetamine 
treated group first showed a decrease in dark period activity through hours 19-21 and 
then showed a normalization of activity afterwards. 
Results summary. Figure 8 shows mean activity (as a percentage of control) 
for the 19-21 hr bin post-treatment for all 6 groups during the control (left) and 
treatment (right) cycles. The amphetamine group alone appeared to decrease in 
activity during the 19-21 hr bin from the control cycles to the treatment cycles. A six 
(treatment groups) by two (treatment conditions) mixed two-way ANOVA was 
conducted. No significant effect of group was obtained, F(5, 56) = 1.557, p > .05. A 
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significant effect of treatment and a significant group by treatment interaction were 
obtained, F(l, 56) = 4.427, p < .05 and F(5, 56) = 3.087, p < .05. 
To investigate the basis of the interaction, a paired t-test was conducted on the 
data for each treatment group. Only the amphetamine group showed a significant 
decline in activity from the control to the drug cycles, t(ll) = 6.547, p < .0001. No 
other group differences were obtained, all ps >.05. 
Conclusions and Discussion 
The purpose of Experiment 1 was to investigate whether stimulation of 
dopamine receptor subtypes had the ability to produce hypo-activity 20 hr later. SKF 
81297, a selective DI receptor agonist, Quinpirole, a selective D2 receptor agonist, 
amphetamine, or saline were administered to rats, and locomotor activity was 
monitored for the next 33 hr. If a selective receptor agonist were to produce hypo-
activity similar to that produced by amphetamine, then amphetamine might produce 
the hypo-activity via that receptor subtype. 
Groups did not differ following control treatments. Consequently, the 
functions provided a good baseline with which to assess the capacity of the different 
drugs to produce significant time- or dose-dependent effects. Drug treatments did 
produce differences in activity. During the first few hours post-treatment, the 0.2 and 
0.4 SKF, the 0.2 and 0.4 Quinpirole, and the 2.0 mg/kg amphetamine groups 
produced very different profiles of immediate period activity. However, the activity 
profiles for all drugs were typical for these particular doses. During the longer-term, 
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different groups again produced differences in activity patterns. Only the 
amphetamine group showed hypo-activity 20 hr post-treatment. Similar to White and 
White (in press) our 2.0 mg/kg amphetamine treatment produced a reduction in 
activity around hour 20, as well as a recovery in activity shortly afterwards in Wistar 
rats. The SKF and Quinpirole treatments did not produce hypo-activity at this time: 
Instead these treatments produced a level of activity during the 19-21 hr bin that was 
comparable to that produced by saline treatment. 
The inability of the selective agonists to produce an activity profile similar to 
that produced by amphetamine suggests that amphetamine-induced hypo-activity is 
not produced by initial stimulation of either the DI or the D2 receptor subtype alone. 
Thus, our hypotheses were not confirmed. 
Certain differences in the effects produced by amphetamine and the selective 
dopamine agonists probably did not account for the failure of the agonists to produce 
hypo-activity. Amphetamine produced hyperactivity in the short-term, but neither 
SKF nor Quinpirole did. Conceivably, the initial hyperactivity may have produced 
fatigue and later hypo-activity. Neither selective agonist produced hyperactivity, so 
there was no fatigue and hypo-activity. 
However, some results are inconsistent with this interpretation. 1.0 mg 
amphetamine produces a greater amount of short term locomotor activity than a 2.0 
mg dose in Wistar rats. However, a 1.0 mg dose does not produce hypo-activity 20 hr 
later, whereas a 2.0 mg dose does (White & White, in press). Therefore, 
amphetamine-induced hypo-activity does not appear to be due to short term 
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hyperactivity that produces a delayed fatigue effect. Similarly, the inability of the 
selective agonists to produce short term hyperactivity may not account for their 
inability to produce hypo-activity. 
Amphetamine and the selective dopamine receptor agonists probably differ in 
half life. Some symptoms of amphetamine-induced acute withdrawal might be seen 
when amphetamine levels fall to a critical level. For example, low doses of dopamine 
agonists activate ventral tegmental area (VTA) auto-receptors and produce catalepsy, 
daytime sleepiness, and REM sleep (Fletcher & Starr, 1988; Wanibuchi & Usuda, 
1990). Perhaps the selective agonists did not produce hypo-activity near hour 20 
because they fell to the critical level with a different time course. 
However, a couple of observations are inconsistent with the possibility that 
the timing of hypo-activity is related in some simple way to drug half-life. First, the 
half-life of amphetamine in rats is about 2 hours, depending on state factors: 
Therefore, essentially no drug is present after 20 hr. Second, the timing of hypo-
activity seems to be dose independent over a wide rage of doses, from 2.0 mg to 10 
mg amphetamine (White & White, 2004). These observations may be more consistent 
with a model of amphetamine induced hypo-activity involving short term saturation 
of some mechanism. Similarly, the inability of the dopamine agonists to produce 
hypo-activity may not have been due to their differences in half-life. 
Amphetamine and the selective agonists may also have differed in receptor 
activation. SKF and Quinpirole may not have produced hypo-activity, because they 
did not produce the same level of short term receptor stimulation that the dose of 
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amphetamine did. Ideally I would have wanted to use doses of SKF and Quinpirole 
that were comparable to amphetamine in DI or D2 activation. Bringing about this 
comparability would be difficult to do, primarily because the modes of action of these 
three drugs are very different. Amphetamine is an indirect agonist of dopamine, 
whereas SKF and Quinpirole are direct agonists ofDl and D2 receptors, respectively. 
The 0.4 doses of both agonists that I used are considered moderately high. By using 
this dose I hoped to produce sufficient receptor activation. In a pilot study involving 
the same animals, we administered 0.8 mg/kg Quinpirole and again did not observe 
hypo-activity 20 hours post-administration. Future studies could use a higher dose 
range more systematically. 
Finally, selective agonists may not have produced hypo-activity around hour 
20 because the cascade of events leading to hypo-activity may be activated by an 
initial Dl and D2 receptor interaction. Dopamine Dl and D2 receptors need to be co-
stimulated in order to produce a wide range of dopamine related behaviors, including 
locomotion. 
Experiment 2: Combined Dopamine Receptor Activation 
Hypo-activity 20 hr after amphetamine administration is dependent upon 
some sort of initial effect. In Experiment 1, initial stimulation of either D 1 or D2 
receptors alone· did not produce this hypo-activity. However, in a prior study, 
administration of the non-selective dopamine receptor agonist apomorphine did 
(White et al., 2002). The apomorphine result, combined with the results of 
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Experiment 1, indicated that initial stimulation of both D1 and D2 receptors may be 
necessary to produce hypo-activity. Many immediate dopaminergic effects depend 
upon an interaction between D 1 and D2 receptors, and these immediate effects could 
produce cascades resulting in longer term effects. Therefore, in Experiment 2, I tried 
to determine whether short-term D 1 and D2 receptor co-stimulation could produce 
hypo-activity 20 hr later. 
To justify this approach, in this section I will review D 1 and D2 receptor 
interaction. First, to indicate when an interaction is absent, I will illustrate the concept 
of double dissociation and of an additive relation between treatments. Next, I will 
explain when an interaction is indicated -- an interaction involves a violation of 
double dissociation -- and then I will review the two kinds of synergistic interactions. 
Because my dependent measure is activity, I will then outline the evidence that 
activity involves an interaction of D 1 and D2 receptors and then describe possible 
mechanisms that might be involved. Next, I will review evidence that other behaviors 
also depend on a D1 and D2 receptor interaction. Finally, I will describe the evidence 
that justifies the particular dose combinations that I chose for Experiment 2. 
Hypothesis. 
• Combined dopamine D1 and D2 receptor activation with agonists SKF 
81297 and Quinpirole will, in a dose dependent manner, produce 
hypo-activity 20-hr post-treatment. 
33 
The ability of the selective agonists (SKF 81297 and Quinpirole) in 
combination to produce hypo-activity would support the hypothesis that short term 
stimulation by amphetamine of both Dl and D2 dopamine receptor subtypes is 
necessary to produce hypo-activity 20 hr later. 
Absence of interaction. The double dissociation technique has been used to 
provide evidence that different mechanisms are responsible for different processes. In 
behavioral pharmacology, a double dissociation would be indicated if agonist and 
antagonist manipulations suggested that receptor subtypes made independent 
contributions to a particular behavior. The pattern of results in the following 
hypothetical example would be consistent with a double dissociation. 
1. A control treatment produced a grooming behavior value of 0. 
2. Treatment with a Dl agonist produced a grooming behavior value of 4. 
3. Treatment with a D2 agonist produced a grooming behavior value of 2. 
4. Combined treatment with the D 1 and D2 agonists used above produced a value of 
6: This result would be consistent with an additive relationship. 
5. Combined treatment with the Dl agonist and a D2 antagonist produced a 
grooming value of 4, that is, the D2 antagonist did not alter the effect of the Dl 
agonist. 
6. Combined treatment with the D2 agonist and a D 1 antagonist produced a 
grooming value of 2, that is, the D 1 antagonist did not alter the effect of the D2 
agonist. 
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The pattern of results in this example suggests that DI and D2 receptor 
subtypes make independent contributions to the same behavior (grooming). 
Interaction. An interaction of receptor subtypes is indicated when agonist and 
antagonist manipulations suggest that the effect of one receptor subtype depends on 
the co-activation of another receptor subtype. Manipulations that produce exceptions 
to the double dissociation rule indicate an interaction. For example, an interaction is 
indicated when treatment effects are non-additive or when the effects of stimulating 
one receptor subtype are altered synergistically by administering antagonists of a 
different receptor subtype. Many dopamine-dependent behaviors, including various 
forms of activity, require an interaction of DI and DI receptors. 
Types of synergistic interactions. A couple of different types of synergistic 
interactions have been defined. A synergistic interaction is present when the effect of 
giving receptor subtype agonists in combination is different than the sum of giving 
the receptor subtype agonists separately. A synergistic interaction can either be 
cooperative or oppositional in nature. A cooperative synergism is present when the 
combination produces an effect that is greater than the sum of the agonists given 
separately, whereas an oppositional synergism is present when the combination 
produces an effect that is smaller. 
The following results illustrate the different synergistic interactions by 
quantifying stereotypy. A DI agonist treatment produces a stereotypy value of 2. A 
D2 agonist treatment produces a stereotypy value of 6. If combined treatment with D 1 
and D2 agonists produces a value significantly greater than 8, such as 12, a 
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cooperative synergistic interaction has occurred. Alternatively, if combined treatment 
with Dl and D2 agonists produces a value significantly less than 8, such as 1, an 
oppositional synergistic interaction has occurred. 
Interaction and activity. As mentioned, the expression of many dopamine 
mediated behaviors requires D 1 and D2 receptor interaction. Various forms of 
activity are examples. In a comprehensive review, Waddington (1993) concluded that 
motor behavior depended upon D 1 and D2 receptor interaction. Forms of activity 
including locomotion, sniffing, jaw movement, stereotypy and turning behavior show 
a cooperative synergism when D 1 and D2 agonists are co-administered (Adachi, 
Ikeda, Hasegawa, Nakamura, Waddington & Koshikawa, 1999; Molloy & 
Waddington, 1985; Robertson & Robertson, 1986; Starr, 1988). Additionally, Koller 
and Herbster (1988) found that Dl agonists combined with D2 agonists elicited levels 
of grooming and sniffing that were similar to those elicited by non-selective 
dopamine agonists. Combined with the previous findings concerning amphetamine 
and apomorphine, these results suggest that longer-term hypo-activity depends on a 
short term interaction of DI and D2 receptors. 
Interaction and mechanism. Dopamine DI and D2 receptors are found in 
many brain regions. Within some neural structures, D 1 and D2 receptors are found 
together, while within other neural structures the receptor subtypes are found 
separately. Thus, two different hypotheses have been proposed regarding the manner 
in which the subtypes interact mechanistically--the co-localization hypothesis and the 
neuro-integrative hypothesis. 
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The co-localization hypothesis proposes that D 1 and D2 receptors residing on 
the membrane of the same neuron interact to produce a particular behavior. Therefore 
interaction occurs directly via a unitary mechanism. Studies involving intracerebral 
injections into the striatum, nucleus accumbens, ventral striatum, and globus pallidus 
have indicated that co-localized Dl and D2 receptors may interact to affect various 
measures of activity (Waddington & Daly, 1993). Furthermore, electrophysiological 
research has shown that cell firing in the striatum, nucleus accumbens and globus 
pallidus may be due to D l/D2 interaction. Guanine nucleotide-binding proteins, 
levels of Na+/K+-ATPase activity and arachidonic acid release within the striatum 
and nucleus accumbens may also be due to D l/D2 interaction (reviewed in 
Waddington & Daly, 1993). 
The neuro-integrative hypothesis proposes that Dl and D2 receptors that 
reside on distant neurons interact to produce a particular behavior. Therefore 
' interaction occurs indirectly via collaterals or efferents of different neurons 
(Robertson & Robertson, 1987). In particular, Dl receptors in the globus pallidus and 
the substantia nigra pars reticulata (areas of the basal ganglia involved in motor 
output) may interact with D2 receptors in the striatum (although they never specify 
which particular nuclei of the striatum). Whether D 1 and D2 interaction within the 
striatum is involved in the expression of a particular behavior may depend on the 
behavior. The neuro-integrative hypothesis, like the co-localization hypothesis, can 
account for regulation of adenylyl cyclase, as well as ascorbic acid release within the 
striatum (Waddington & Daly, 1993). 
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The co-localization and neuro-integrative hypotheses are still being debated. 
Interaction and other behaviors. In addition to activity being affected by 
dopamine D 1/D2 receptor interaction, other behaviors and processes also appear to 
depend upon an interaction. Dopamine is involved in motor behavior and in reward 
and learning processes, thus it is plausible that many behaviors and processes are 
influenced by the interaction of D 1 and D2 receptors. 
Dopamine receptor interaction modulates arousal and sleep (Ongini, 1993). 
D 1 agonists induce EEG arousal and enhance wakefulness, whereas D 1 antagonists 
induce sedation and sleep. Furthermore, D2 agonists induce arousal, but D2 
antagonists have no effect on sleep. An interaction between DI and D2 receptors may 
induce arousal and sedation, but REM sleep appears to be regulated by just D 1 
receptors. 
Dopamine receptor interaction is involved in aspects of food intake (Cooper & 
Al-Naser, 1993). DI receptor agonists do not appear to affect the rate of eating, but 
they do reduce the frequency of feeding. Alternatively, D2 receptor agonists appear to 
reduce the rate of eating. Moreover, the effects are synergistic when agonists are 
combined. An anorectic effect is elicited when DI and D2 receptors are stimulated 
simultaneously. This potentiation in food reduction is found with both selective and 
nonselective, as well as with direct and indirect, dopamine agents. Furthermore, the 
effect also appears to be dose dependent. 
On the other hand, drug discrimination does not appear to depend on 
dopamine receptor interaction (Nielsen, 1993). D 1 agonists failed to substitute for a 
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D2 cue, and, similarly, D2 agonists failed to substitute for a D 1 cue. Different direct 
and indirect mixed Dl/D2 agonists could be discriminated (amphetamine, 
apomorphine, cocaine). The findings suggested that D 1 and D2 receptors are non-
interacting in the drug discrimination model. In other words, a D 1 and D2 interaction 
is not necessary for drug discrimination. 
The relation between D l/D2 interaction and behavior is complicated. Certain 
behaviors depend on simultaneous stimulation of receptor subtypes, whereas others 
do not. Furthermore, the effects appear to be dose dependent as well as dependent on 
the sensitivity of the behavioral measure. 
Interaction and dose issues. The interaction ofDl and D2 receptors appears to 
depend upon certain threshold levels of activation for each receptor subtype. Braun 
and Chase (1986) suggested that concurrent stimulation of both Dl and D2 receptors 
is necessary for the expression of behaviors that are seen with non-selective agonists 
such as apomorphine and amphetamine. The study suggested that the nature or the 
quality of the behavioral response is a function of the ratio of DI and D2 receptor 
stimulation. Furthermore, the response depends upon the level of the underlying DI 
receptor tone. The authors suggest that "in order to investigate the dopaminergic 
contribution in a particular behavior, one must fix the dose of the D2 stimulation and 
use a range of Dl stimulation." Waddington and Daly (1993) also suggested that Dl 
receptor stimulation is needed in order to obtain expression of D2 mediated 
behaviors. The level of DI tone appears to exert important qualitative and 
quantitative synergistic control of D2-stimulated motor activity. That is, increases and 
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decreases in D 1 stimulation appear to enhance and attenuate the intensity of D2 
agonist-induced behaviors such as stereotypy. 
The concept that one receptor subtype gates or enables the function of the 
other appears in much of the Dl/D2 interaction literature, although the reason for this 
segregation of receptor subtype function is still unclear. Behavioral and physiological 
explanations have been given for why a tonic dose is important in D l/D2 interaction. 
Waddington (1986, 1993) suggested that the D2 system influences the mode of 
expression for a behavior, whereas the D 1 system influences the level of D2 activity. 
Thus, Dl receptor stimulation can enhance or block normal behaviors. Similarly, 
when a D2 agonist is given, a stereotyped mode of behavior is selected that can then 
be either enhanced or blocked by D 1 agonists or antagonists. Waddington also 
suggested that the normal level of tonic D 1 activity is high. Other researchers such as 
LaHoste and Marshall (1990) suggested that the effects ofDl tonic activation may be 
due to interactions with GABA. GABA activity is modulated by Dl receptors in the 
substantia nigra pars reticulata (SNr), which in turn influences motor activity. The 
only way for a D2 agonist to activate GABA is by first stimulating D 1 receptors in 
the SNr. Therefore, the researchers suggested that GABA might regulate D 1 tone and 
Dl behavioral influence. 
Many dopamine mediated effects depend on threshold doses of agonists and 
an appropriate balance of receptor activation. The reason why a tonic dose of D 1 
activation is necessary for the expression of behavior is not understood. However, to 
increase the likelihood of using a combination that has these properties and to elicit 
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hypo-activity around hour 20, I used an increasing dose of SKF in combination with a 
fixed, moderately-high dose of Quinpirole. 
Methods 
Subjects 
The subjects were 32 male rats of the Wistar strain, purchased from Harlan 
(Indianapolis, IN). As in Experiment 1, prior to the start of the study all rats were 
housed in pairs in the departmental colony in a temperature of 20°C - 22°C and on a 
12-hr light/ 12-hr dark cycle. Rats had free access to food (5001 Rodent Diet, Lab 
Diet) and water and weighted between 300 and 400 g at the start of the experiment. 
Animals were treated in accordance with ethical guidelines established by the 
National Institutes of Mental Health. 
Apparatus 
Eight of the sixteen stations used in Experiment 1 were utilized in Experiment 
2. The stations were housed in one of the rooms from that experiment. The same 
control equipment was used. 
Drugs 
0.2 mg/ml, 0.4 mg/ml or 0.8 mg/ml SKF 81297 (Sigma) was mixed with 0.4 
mg/ml Quinpirole (Sigma) in saline. All drugs were injected subcutaneously in the 
back of the neck in a volume of 1.0 ml/kg. Saline was used as the control treatment. 
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Procedure 
Figure 9 displays a schematic diagram of the basic procedure. Once a day for 
3 days prior to the start of each study animals were handled, weighed and vigorously 
rubbed on the nape of the neck for several seconds. Each study involved 2 groups run 
in the stations during alternating administration cycles. During a typical 
administration cycle animals in the first group were taken out of the colony and 
placed in individual stations 2 hr prior to lights on. At lights on, each animal was 
briefly removed from the station and treated. Treatment involved subcutaneous 
injection into the nape of the neck. After administration, the rat was placed back into 
the apparatus where activity could be monitored for the next 33 hr. After 33 hr 
animals were removed from the stations and placed back into the departmental 
colony. At this time, maintenance of the apparatus occurred. Maintenance consisted 
of wiping down each pan, adding new top soil, and replenishing food and water. The 
second group was then exposed to the same conditions beginning the next day. All 
rats were housed on the same 12-hr light/ 12-hr dark cycle either in the departmental 
colony on non-testing days or in the apparatus on testing days. Throughout the 
experiment, animals had free access to food and water. 
Each group received 2 administration cycles involving control treatments 
followed by 2 administration cycles involving drug treatments. Consequently, the 2 
groups were alternated in the stations for a total of 4 administration cycles each. 
Treatments for a particular group were always separated by at least 96 hr. During the 
control treatment cycles all animals were treated with 0.5 ml saline. During the drug 
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treatment cycles animals were treated with 1.0 ml/kg of different combinations of 
drug. For each group the dose of Quinpirole was fixed, but across groups the dose of 
SKF 81297 with which Quinpirole was combined varied. The 4 treatment groups 
were 0.0 SKF/ 0.4 Quinpirole, 0.2 SKF/ 0.4 Quinpirole, 0.4 SKF/0.4 Quinpirole, and 
0.8 SKF/ 0.4 Quinpirole. 
Data Analysis 
The tracking software was again used to quantify total distance moved for 
each rat into 10-min bins. For each rat activity was quantified beginning with the 10-
min bin following treatment. Again, data were then combined into 33 1-hr bins for 
each rat. Similar to Experiment 1, all hourly activity totals were expressed as a 
percentage of each rat's mean control value. Hourly percent control values were then 
averaged for each rat across the 2 control cycles and the 2 treatment cycles. Activity 
was also averaged into 3-hr bins for each rat. Activity was then averaged across 
subjects in a treatment group. 
Changes in immediate activity (hours 1-6 post-treatment) and longer-term 
activity (hours 7-33 post-treatment averaged into 3-hr bins) were analyzed with 
within-subjects analysis of variances (ANOVAs). One-way within subjects ANOVAs 
were performed on significant main effects. All significant results were followed-up 
with Fisher's PLSD post hoc analyses or paired t-tests. 
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Results 
Immediate effects. Figure 10 shows mean activity (as a percentage of control) 
for the first 6 hr post-treatment for 0.0 SKF/ 0.4 Quinpirole and 0.2 SKF/ 0.4 
Quinpirole combination groups during control and drug cycles. Figure 11 shows 
similar data for 0.4 SKF/ 0.4 Quinpirole and 0.8 SKF/ 0.4 Quinpirole groups. In order 
to evaluate how activity changed from control to drug cycles, a series of analyses 
were done on the data for each group. First, to assess overall effects, a two (treatment 
condition [control or drug]) by six (post-treatment hour) within subjects two-way 
ANOV A was performed ("overall analysis"). Next, to investigate changes in activity 
across post-treatment hours, two separate one-way within subjects ANOV As were 
done on control and treatment data ("time analysis"). Fisher's PLSD post hoc analysis 
was used to examine significant effects. Finally, to compare activity during control 
and drug cycles at each hour post-treatment, six separate within subjects t-tests were 
carried out ("condition analysis"). 
0.0 SKF/ 0.4 Quinpirole group. In the overall analysis no significant effect of 
condition was obtained, F(l, 7) = 1.873, p > .05. A significant effect of hour and a 
significant condition by hour interaction were obtained, Fs(5, 35) = 15.874 and 4.527, 
ps < .0001 and .01. The time analyses showed that, for both control and drug cycles, 
activity changed significantly over time, F(5, 35) = 23.638, p < .0001 and F(5, 35) = 
8.446, p < .0001. Activity during control cycles was elevated during the first hour 
compared to all other hours post-treatment, ps < .0001. Activity during drug cycles 
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Figure JO. Mean activity during hr 1-6 post-administration for 0.0 SKF/ 0.4 
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was elevated during hours 1 and 2 compared to all other hours post-treatment, ps < 
.01. The condition analysis showed that activity was elevated during control cycles 
relative to drug cycles during hour 5 post treatment, 1(7) = 3.147, p < .05 
0.2 SKF/ 0.4 Quinpirole group. In the overall analysis no significant effect of 
condition was obtained, F(l, 7) = 0.033, p > .05. A significant effect of hour and a 
significant condition by hour interaction were obtained, Fs(5, 35) = 31.149 and 
51.805, ps < .0001. According to the time analysis, for control and drug cycles, 
activity changed significantly over time, F(5, 35) = 51.805, p < .0001 and F(5, 35) = 
78.6060, p < .0001. Activity during control cycles was elevated during the first hour 
compared to all other hours post-treatment, ps < .0001. Activity during hour 2 was 
elevated compared to hours 3, 5 and 6 post-treatment, ps < .05. Furthermore, activity 
during hour 4 was elevated compared to hours 3, 5 and 6 post-treatment, ps < .05. 
Activity during drug cycles was elevated during the first hour compared to all other 
hours post-treatment, ps < .0001. According to the condition analysis, differences in 
activity were obtained during hours 1, 3 and 4 post-treatment, ts(?) = -2.379, 2.915 
and 3.381, ps < .05. Activity of drug cycles was higher during the first hour, and 
activity of control cycles was higher during hours 3 and 4. 
0.4 SKF/ 0.4 Quinpirole group. In the overall analysis no significant effect of 
condition was obtained, F(l, 7) = 4.074, p > .05. A significant effect of hour and a 
significant interaction were obtained, Fs(5, 35) = 53.944 and 2.746, ps < .0001 and 
.05. According to the time analysis, for both control and drug cycles, activity changed 
significantly over time, F(5, 35) = 11.833, p < 0001 and F(5, 35) = 25.526, p < .0001. 
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Activity during control cycles was elevated during the first hour compared to all other 
hours post-treatment, ps < .0001. The same was true for drug cycles, ps < .0001. 
According to the condition analysis a difference in activity between control and drug 
treaiments was obtained during the first hour, when activity of drug cycles was 
elevated, t(7) = -3.136, p < .05. 
0.8 SKF/ 0.4 Quinpirole group. In the overall analysis no significant effect of 
condition was obtained, F(l, 7) = 1.183, p > .05. A significant effect of hour and a 
significant interaction were obtained, Fs(5, 35) = 29.260 and 5.026, ps < .0001 and 
.01. According to the time analysis, for control and drug cycles, activity changed 
significantly over time, F(5, 35) = 18.833, p < .0001 and F(5, 5) = 17.497, p < .0001. 
Activity during control cycles was elevated during the first hour compared to all other 
hours post-treatment, ps < .0001. The same pattern was obtained during drug cycles, 
ps < .0001. According to the condition analysis, a difference in activity was obtained 
during hour 3 post-treatment, when activity of control cycles was elevated, t(7) = 
2.448, p < .05. 
Figure 12 shows activity (as centimeters moved) in 10-min bins for the first 3-
hr post-treatment. The figure shows activity for each group during drug cycles. All 
functions were biphasic. Adding each dose of SKF seemed to partially alleviate the 
hour 1 inhibition of activity produced by Quinpirole. 
Longer-term effects. Figure 13 shows mean activity (as a percentage of 
control) averaged across 3-hr bins for hours 7-33 post treatment for 0.0 SKF/ 0.4 
Quinpirole and 0.2 SKF/ 0.4 Quinpirole combination groups during control and drug 
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cycles. Figure 14 shows the same data for 0.4 SKF/ 0.4 Quinpirole and 0.8 SKF/ 0.4 
Quinpirole groups. In order to evaluate how activity changed from control to drug 
cycles, a series of analyses, similar to those done on immediate period activity, were 
planned. For the overall analysis a two (treatment condition) by nine (3-hr bin post-
treatment) within subjects two-way ANOV A was performed. When a significant 
effect of treatment or a significant treatment by bin interaction was obtained, time 
analysis and condition analysis were done. In the time analysis, to investigate 
changes in dark-period activity across 3-hr bins, two separate one-way within subjects 
ANOVAs were done on control and treatment data. Fisher's PLSD post hoc analyses 
were used to interpret significant effects. In the condition analysis, activity for control 
and drug cycles was compared at each of the 3-hr dark-period bins with four separate 
within subjects t-tests. 
0.0 SKF/ 0.4 Quinpirole group. In the overall analysis no significant effect of 
condition and no significant condition by hour interaction were obtained, F(l, 7) = 
0.469, p > .05 and F(8, 56) = 0.621, p > .05. A significant effect of hour was 
obtained, F(8, 56) = 21.143, p < .0001. Fisher's PLSDs were used to interpret the 
significant main effect of 3-hr bin. Activity was elevated during dark-period bins 
relative to light-period bins, and it was elevated during bin 22-24 relative to other 
dark-period bins, ps < .05. 
0:2 SKF/ 0.4 Quinpirole group. The same pattern of results was seen. In the 
overall analysis no significant effect of condition and no significant interaction of 
condition and 3-hr bin were obtained, F(l, 7) = 0.484, p > .05 and F(8, 56) = 1.787, p 
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> .05. A significant effect of hour was obtained, F(8, 56) = 32.366, p < .0001. Again, 
activity was elevated during dark-period bins relative to light-period bins, and it was 
elevated during bin 22-24 relative to other dark-period bins, ps < .05. 
0.4 SKF/ 0.4 Quinpirole group. In the overall analysis no significant effect of 
condition was obtained, F(l, 7) = 1.939, p > .05. A significant effect of 3-hr bin and a 
significant condition by 3-hr bin interaction were obtained, Fs(8, 56) = 145.688 and 
9.562, ps < .0001. In the time analysis, for control and drug cycles, activity changed 
significantly over time, F(8, 56) = 83.748, p < .0001 and F(8, 56) = 90.518, p < 
.0001. For control cycles activity was elevated during the 13-15 hr bin compared to 
the 16-18, 19-21 and 22-24 hr bins, ps < .01. For drug cycles, activity was elevated 
during the 13-15 hr bin compared to the 16-18 and 19-21 hr bins, ps < .05 and .001. 
Activity was also elevated during the 22-24 hr bin compared to all other dark period 
bins, ps < .0001. According to the condition analysis, compared to control, drug cycle 
activity was lower during the 13-15, 16-18 and 19-21 hr bins, ts(7) = 2.858, 2.60 and 
4.247, ps < .05 - .01, and higher during the 22-24 hr bin, t(7) = -3.367, p < .05. To 
summarize, during the drug condition activity appeared to decline during the 19-21 hr 
bin and to rebound during the 22-24 hr bin 
0.8 SKF/ 0.4 Quinpirole group. According to the overall analysis no 
significant effect of condition was obtained, F(l, 7) = 0.246, p > .05. A significant 
effect of 3-hr bin and a significant interaction of condition and 3-hr bin were 
obtained, Fs(8, 56) = 75.277 and 8.102, ps < .0001. According to the condition 
analysis, for both control and drug cycles, activity changed significantly over time, 
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F(8, 56) = 69.927, p < .0001 and F(8, 56) = 42.415, p < .0001. For control cycles 
activity was elevated during the 13-15 hr bin compared to the 16-18 and 22-24 hr 
bins, ps < .05 and .01. Additionally, activity was elevated during the 19-21 hr bin 
compared to the 16-18 and 22-24 hr bins, ps < .05 and .001. For drug cycles, activity 
was elevated during the 22-24 hr bin compared to all other dark period bins, ps < 
.005. The condition analysis indicated that activity was lower during drug cycles 
compared to control cycles during the 13-15 and 19-21 hr bins, ts(7) = 4.229 and 
3.196, ps < .01 and .05. Activity then increased during drug cycles compared to 
control cycles during the 22-24 hr bin, t(7) = -2.433, p < .05. 
Results summary. Figure 15 shows activity for all combination groups during 
the 19-21 hr bin post-treatment. Drug data were expressed as a percentage of control 
for each subject, and t-tests were used to see if groups' means were significantly 
different from 100%. The 2 high dose combination groups had decreased activity 
during the 19-21 hour hr bin, ts(7) = -4.510 and -3.137, ps < .01 and .05, whereas the 
2 low dose combination groups did not, ts(7) = -0.333 and 0.171,ps > .05. 
Conclusions and Discussion 
The purpose of Experiment 2 was to investigate whether co-stimulating D 1 
and D2 receptor subtypes had the ability to produce hypo-activity 20 hr later. A range 
of doses of the D 1 agonist SKF 81297 was combined with a dose of the D2 agonist 
Quinpirole. Different groups of rats were given 0.0 SKF/ 0.4 Quinpirole, 0.2 SKF/ 0.4 
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Quinpirole, 0.4 SKF/ 0.4 Quinpirole or 0.8 SKF/ 0.4 Quinpirole, and activity was 
then monitored for 33 hr. The ability of combined agonists to produce hypo-activity 
would be consistent with the possibility that concurrent stimulation of D1 and D2 
receptors induces amphetamine-induced hypo-activity. 
With respect to short term effects, only the 0.0 SKF/ 0.4 Quinpirole treatment 
group showed an effect of drug on activity through hour 2 post-administration. The 
function for this combination group was biphasic, which is typical of a 0.4 mg/kg 
dose of Quinpirole. The other three combination groups (0.2 SKF/ 0.4 Quinpirole, 0.4 
SKF/ 0.4 Quinpirole and 0.8 SKF/ 0.4 Quinpirole) had a high level of activity only 
during the first hour post-treatment 
Groups showed different patterns of longer term activity following treatment 
compared to control. Specifically, the two lower dose combination groups (0.0 SKF/ 
0.4 Quinpirole and 0.2 SKF/ 0.4 Quinpirole) did not display hypo-activity during the 
19-21 hr bin. However, the two higher dose combination groups (0.4 SKF/ 0.4 
Quinpirole and 0.8 SKF/ 0.4 Quinpirole) did display such hypo-activity. Additionally, 
during drug cycles the two higher dose combination groups also showed levels of 
activity that were elevated during the 25-27 hr bin. This pattern of hypo-activity 
around hour 20 and of enhanced activity near hour 25 is very similar to the activity 
pattern seen following amphetamine administration. These results obtained with the 
high dose combination groups suggest that amphetamine-induced hypo-activity may 
require initial co-activation of D 1 and D2 receptors. Additionally, the inability of the 
0.2 SKF/ 0.4 Quinpirole combination to produce hypo-activity suggests that this 
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behavior is dependent not only on co-activation, but also on dose or amount of 
receptor stimulation. 
Interestingly, these data from Experiment 2 suggest that an oppositional 
interaction in the short-term may be correlated with hypo-activity in the longer-term. 
Compared to the Quinpirole-alone group, the 0.4 SKF/ 0.4 Quinpirole group had a 
higher initial level of activity. The function for this dose combination had an earlier 
asymptote and a quicker decline to zero. I will have more to say about the 
implications of short term receptor interaction in the general discussion when I make 
comparisons across experiments. 
The results of Experiment 2 provide further evidence regarding the processes 
and mechanisms that might be responsible for amphetamine-induced hypo-activity. 
The high dose treatment combinations did not produce levels of immediate 
activity like that of amphetamine. The levels of activity produced by these 
combinations might not be expected to produce fatigue. And yet, like amphetamine, 
these combinations did produce longer-term hypo-activity. Thus, amphetamine-
induced hypo-activity may not be due to a fatigue effect. 
The pharmacokinetic profiles of the agonists used in this research are not 
known. Given the nature of their short term effects on activity, they probably have 
short half-lives that are very different from one another and from the half-life of 
amphetamine. The fact that both the combined agonists and amphetamine can 
produce hypo-activity 20 hr after administration provides further evidence that 
expression of hypo-activity is not related to drug half-life. 
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In Wistar rats, 2.0 mg/kg amphetamine is needed to produce hypo-activity 20 
hr after administration. In the present experiment, the 0.4 SKF/ 0.4 Quinpirole 
combination produced a similar effect. Perhaps amphetamine produces hypo-activity 
when it brings about a level of DI and D2 receptor activation that is similar to that 
produced by a 0.4 SKF/ 0.4 Quinpirole dose combination. 
General Discussion 
Amphetamine administration produces hypo-activity 20 hr later in rats (White 
et al., 2004; White & White, in press). The purpose of this research was to investigate 
whether specific dopaminergic mechanisms might contribute to this amphetamine-
induced effect. Two experiments were conducted in order to carry out this purpose. 
The locomotor activity of rats was recorded after administration of drug. SKF 81297 
and Quinpirole, D 1 and D2 receptor agonists, respectively, were administered. In 
Experiment 1, dopamine receptor subtype agonists administered alone did not 
produce hypo-activity 20 hr later. In Experiment 2, the dopamine agonists 
administered in combination did produce such hypo-activity. Co-stimulating DI and 
D2 receptors produced a longer-term activity pattern that was similar to that produced 
by amphetamine administration. 
An oppositional interaction reflected in short-term activity may be correlated 
with hypo-activity in the longer-term. Less short term activity occurred following the 
0.4 SKF/ 0.4 Quinpirole combination (Experiment 2, Figure 12) than would be 
expected by summing the effects of the agonists given separately (Experiment 1, 
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Figure 16. Activity during first 3 hr post-administration in 3 min bins for 0.4 mg SKF 
and 0.4 mg Quinpirole groups from Experiment I and 0.4 mg SKF/ 0.4 mg 
Quinpirole group from Experiment 2 during drug cycles. 
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Figure 5). The relevant data are re-plotted in Figure 16. The figure shows centimeters 
moved every 10 min following treatment with 0.4 mg/kg SKF, 0.4 mg/kg Quinpirole, 
or the combination. The fact that short term D 1/ D2 synergism might have longer 
term consequences for behavior seems to be a novel finding. The functions in Figure 
16 were from different experiments entailing different methods, so conclusions are 
tentative. 
As of now, the location of the mechanism involved in the induction of hypo-
activity is not known. This research suggests that the location is an area where the 
dopamine receptor subtypes converge. Furthermore, the area of convergence may be 
involved in motor control. Potential areas include the nucleus accumbens, striatum, 
cingulate gyrus and substantia nigra. 
Treatments that produce hypo-activity in the longer term produce enhanced 
activity in the short term. Opponent process theory provides one explanation for this 
reversal in measure. According to opponent process theory, a treatment that produces 
an intense state later produces a rebound state having many of the opposite 
characteristics. Amphetamine treatment produces an intense state characterized by 
hyperactivity and hedonic effects. The hypo-activity observed later may reflect a 
rebound state having the opposite characteristics, that is, it may indicate the presence 
of a "crash" or acute withdrawal. 
According to the theory, the initial response to drug would produce neuro-
adaptations that outlast the initial drug response and that mediate this crash. In the 
case of amphetamine, the initial response and the neuro-adaptations might occur in 
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the reward system and involve dopamine. The processes of within system adaptation 
and between systems adaptation suggest further details. 
In a within system adaptation overlapping mechanisms mediate the initial 
state and the rebound state. In Experiment 2, higher dose combinations produced 
increased activity in the shorter term and hypo-activity in the longer term. This result 
may have reflected a within system adaptation. For example, the site of D 1 and D2 
receptor convergence may have contributed to both short term hyperactivity and 
longer term hypo-activity. In this case, the short term Dl and D2 receptor synergism 
with respect to activity might not just be correlated with later hypo-activity but may 
be causally related to it. Amphetamine may produce hypo-activity via such a within 
system adaptation. 
Alternatively, higher dose combinations may have induced hypo-activity via a 
between systems adaptation. In a between systems adaptation different mechanisms 
mediate the initial state and the rebound state. For example, the initial state produced 
by the higher dose combinations in Experiment 2, and indicated by hyperactivity, 
may have been mediated by the reward system. On the other hand, the rebound state, 
indicated by hypo-activity, may have been mediated by the sleep system. 
Amphetamine and apomorphine have both been shown to produce hypo-
activity 20 hr post-administration. The results of this research suggest that Dl and D2 
receptor co-activation may be necessary to induce this effect. Several symptoms of 
acute withdrawal are present 20 hr after amphetamine receipt, including a 
Haloperidol-like cue state, decreased motivation to obtain natural reward, REM sleep 
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rebound and hypothermia (Barr & Phillips, 1992; Barret et al., 1992; Edgar & Seidel, 
1997; Eikelboom & Stewart, 1981). Whether D1 and D2 receptor co-activation is 
necessary to produce these symptoms is unknown. Hypo-activity may be a correlate 
of acute withdrawal. 
If hypo-activity is indeed an indicator of acute withdrawal, then the methods 
used here may provide a convenient animal model with which to study the 
determinants of this state. 
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